Technical Analysis for DRNA - Dicerna Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 16.295 -0.58% -0.10
DRNA closed up 3.73 percent on Friday, October 18, 2019, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Nov 4

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical DRNA trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish -0.58%
Pocket Pivot Bullish Swing Setup -0.58%
Upper Bollinger Band Walk Strength -0.58%
Above Upper BB Strength -0.58%
Overbought Stochastic Strength -0.58%
Upper Bollinger Band Touch Strength -0.58%
180 Bullish Setup Bullish Swing Setup 3.13%
Stochastic Reached Overbought Strength 3.13%
Upper Bollinger Band Walk Strength 3.13%
Above Upper BB Strength 3.13%

Older signals for DRNA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company's development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including maple syrup urine disease, familial amyloid polyneuropathy or cardiomyopathy, alpha-1 anti-trypsin hepatocyte inclusions, hemophilia A and B, paroxysmal nocturnal hemoglobinuria, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated; and a product candidate targeting the oncogene KRAS. The company has a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. for the research, development, and commercialization of DsiRNA molecules and drug delivery technologies for therapeutic targets in oncology; and a license agreement with City of Hope, an academic research and medical center, to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.
Medicine Biopharmaceutical Cancer Diseases Disease Cancers Enzymes Paroxysmal Nocturnal Hemoglobinuria Liver Liver Diseases Cardiomyopathy Carcinogenesis Familial Amyloid Polyneuropathy Hemophilia A Ras Subfamily C Met Drug Delivery Technologies Hyperoxaluria Primary Hyperoxaluria Treatment Of Various Cancers
Is DRNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 16.95
52 Week Low 9.31
Average Volume 396,458
200-Day Moving Average 13.2734
50-Day Moving Average 14.3312
20-Day Moving Average 14.646
10-Day Moving Average 14.852
Average True Range 0.7027
ADX 18.08
+DI 33.476
-DI 12.0341
Chandelier Exit (Long, 3 ATRs ) 14.4119
Chandelier Exit (Short, 3 ATRs ) 15.2981
Upper Bollinger Band 15.8574
Lower Bollinger Band 13.4346
Percent B (%b) 1.22
BandWidth 16.542401
MACD Line 0.3264
MACD Signal Line 0.1386
MACD Histogram 0.1879
Fundamentals Value
Market Cap 341.64 Million
Num Shares 20.8 Million
EPS -3.20
Price-to-Earnings (P/E) Ratio -5.12
Price-to-Sales 155.10
Price-to-Book 7.93
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.64
Resistance 3 (R3) 17.54 17.03 17.43
Resistance 2 (R2) 17.03 16.71 17.08 17.36
Resistance 1 (R1) 16.71 16.52 16.87 16.81 17.29
Pivot Point 16.20 16.20 16.28 16.25 16.20
Support 1 (S1) 15.88 15.88 16.04 15.98 15.49
Support 2 (S2) 15.37 15.69 15.42 15.42
Support 3 (S3) 15.05 15.37 15.35
Support 4 (S4) 15.15